DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Telli ML, Turner NC, Mailliez A. et al.
ABRAZO: Exposure-efficacy and -safety analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in a phase 2 open-label trial [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5–9; San Antonio, TX. Philadelphia (PA): AACR.
Cancer Res 2018;
78: Abstr.. P1-14-03
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.